Seasoned operator and investor focused on technology and growth-stage companies, Damir Durkovic combines founder-level operating experience with early-stage venture investing and strategic advisory work. He has led product, go-to-market and M&A initiatives in software and fintech businesses, sits on several private company boards, and sources deals across EMEA. Educational foundation includes engineering and business studies. Market-facing profile emphasizes scaling revenue, capital strategy and exit planning.
Seasoned operator and investor focused on technology and growth-stage companies, Damir Durkovic combines founder-level operating experience with early-stage venture investing and strategic advisory work. He has led product, go-to-market and M&A initiatives in software and fintech businesses, sits on several private company boards, and sources deals across EMEA. Educational foundation includes engineering and business studies. Market-facing profile emphasizes scaling revenue, capital strategy and exit planning.
Combines a founder-operator lens with disciplined early-stage venture investing, prioritizing SaaS and fintech businesses with clear product-market fit and repeatable revenue models. Focuses on backing teams where he can add tangible go-to-market and product scaling expertise, structuring capital to bridge growth to exit and de-risk through staged milestones. Investment horizon is growth-to-exit, favoring revenue-driven metrics, unit-economics improvement, and pragmatic M&A-aware planning while maintaining concentrated, board-level active portfolio involvement.
Combines a founder-operator lens with disciplined early-stage venture investing, prioritizing SaaS and fintech businesses with clear product-market fit and repeatable revenue models. Focuses on backing teams where he can add tangible go-to-market and product scaling expertise, structuring capital to bridge growth to exit and de-risk through staged milestones. Investment horizon is growth-to-exit, favoring revenue-driven metrics, unit-economics improvement, and pragmatic M&A-aware planning while maintaining concentrated, board-level active portfolio involvement.
| Trades 8092 | Longs Won 4046/8092 50% | Profit Factor 1.93 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $654,070.37 |
| Average Win $235,062.42 | Best Trade (Jun 30) $26.62M | Sharpe Ratio -20.84 |
| Average Loss -$121,568.7 | Worst Trade (Sep 01) -$5.82M | Z-Score -3.01 (100%) |
| Commissions $0 | Avg. Trade Length 5m | Expectancy $56,746.86 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 20,833 | 18,750 | 16,667 | 14,583 | 12,500 | 10,417 | 8,333 | 6,250 | 4,167 | 2,083 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
A Agilent Technologies Inc. | 14,321 | $1.63M | $2.12M | - | $490,637.52 | 30.06% | 0.0 |
AA Alcoa Corporation | 51,792 | $3.44M | $2.57M | - | -$866,998.29 | -25.24% | -3.182% |
AAL American Airlines Group Inc. | 209,443 | $2.25M | $3.15M | - | $904,793.74 | 40.22% | +0.871% |
AAON Aaon Inc. | 5,594 | $709,655 | $476,776.62 | - | -$232,878.38 | -32.82% | 0.0 |
ABBV AbbVie Inc. | 64,317 | $16.18M | $16M | - | -$185,233.72 | -1.14% | 0.0 |
ABNB Airbnb, Inc. | 95,328 | $13.64M | $17.17M | - | $3.53M | 25.85% | 0.0 |
ABT Abbott Laboratories | 105,540 | $12M | $11.71M | - | -$293,448.15 | -2.45% | 0.0 |
ACA Arcosa Inc. | 8,550 | $1.24M | $1.24M | - | -$2,052.5 | -0.17% | 0.0 |
ACDC ProFrac Holding Corp. | 27,022 | $156,998 | $138,893.08 | - | -$18,104.92 | -11.53% | 0.0 |
ACI Albertsons Companies, Inc. | 104,471 | $1.41M | $1.25M | - | -$158,796.29 | -11.23% | 0.0 |
ACM Aecom | 42,958 | $3.24M | $2.62M | - | -$616,191.75 | -19.03% | 0.0 |
ACMR Acm Research Inc. | 2,068 | $262,409 | $168,045.68 | - | -$94,363.32 | -35.96% | 0.0 |
ADC Agree Realty Corporation | 76,208 | $5.65M | $5.67M | - | $15,645.98 | 0.28% | 0.0 |
ADEA Adeia Inc. | 7,718 | $185,463.75 | $216,952.98 | - | $31,489.23 | 16.98% | 0.0 |
ADM Archer-Daniels-Midland Co | 26,035 | $1.5M | $2.08M | - | $579,018.68 | 38.69% | 0.0 |
ADMA Adma Biologics Inc. | 22,602 | $189,179 | $221,047.56 | - | $31,868.56 | 16.85% | 0.0 |
ADPT Adaptive Biotechnologies Corporation | 5,081.25 | $435,971.25 | $128,301.56 | - | -$307,669.69 | -70.57% | 0.0 |
ADTN Adtran Holdings, Inc. | 23,203 | $277,883.53 | $189,336.48 | - | -$88,547.05 | -31.86% | 0.0 |
AEE Ameren Corporation | 68,416 | $7.54M | $7.45M | - | -$98,635.64 | -1.31% | 0.0 |
AEG Aegon N.V. | 127,979 | $951,888.18 | $1.2M | - | $251,114.42 | 26.38% | 0.0 |